stockrow
Friday 6 November 2026
Export PVLA’s income statement to Excel — free account
Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
174.08
17.23
+10.99%
Follow PVLA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
20.97 | 28.73 | 5.11 | 6.38 | |
Current Ratio |
21.18 | 28.88 | 5.20 | 6.49 | |
Net Debt/EBITDA |
11.71 | 17.63 | 5.13 | 6.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.59 | 0.69 | 0.39 | 0.69 | |
Interest Coverage |
(9.27) | (7.29) | (6.50) | (6.74) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.89) | (0.83) | (0.44) | (0.71) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.89) | (0.83) | (0.44) | (0.71) | |
Cash per Share |
17.46 | 20.01 | 5.15 | 5.75 | |
Shareholders Equity per Share |
15.11 | 17.75 | 2.49 | 3.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.11 | 17.75 | 2.49 | 3.50 | |
Free Cash Flow |
(12.84) | (10.86) | (4.93) | (7.88) | |
Working Capital |
241.08 | 254.12 | 47.64 | 56.63 | |
Net Current Asset Value |
216.39 | 231.79 | 27.41 | 38.68 | |
| Other line items | |||||
Average Receivables |
— | — | — | 1.55 | |
Average Payables |
5.67 | 4.94 | 4.59 | 2.14 | |
Average Assets |
163.63 | 171.60 | 73.90 | 43.73 | |
Average Common Equity |
132.32 | 143.95 | 45.30 | 27.48 |
Columns are period end dates · fundamentals updated 26 Oct 2026